New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For NVS;MOS;SCCO;ADM;IP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
October 30, 2014
11:20 EDTIPKapStone jumps after saying MLP being studied
Shares of KapStone Paper (KS) are rising after the company said on its third quarter earnings conference call that it is studying a potential master limited partnership, or MLP. WHAT'S NEW: KapStone management stated that the company has filed a request for a PLR, or private letter ruling, with the IRS regarding a potential MLP, though added that the move "does not indicate a decision" on its future direction. "We're only just trying to get in line. We are working with a good group of outside advisers and we remain intrigued by the concept and are studying our options," KapStone management stated. KapStone cautioned that the company still has not reached a designation and an MLP plan has not been submitted to its board for approval. Last night, KapStone reported third quarter adjusted earnings per share of 60c and revenue of $598.1M, which missed consensus forecasts of 67c and $604.18M, respectively. WHAT'S NOTABLE: On July 24, Bloomberg reported that Richard Perry's Perry Capital took positions or increased holdings in containerboard names KapStone, International Paper (IP), RockTenn (RKT) and Packaging Corp. (PKG). Perry stated in the fundís Q2 letter the he believes the companies can create master limited partnerships for their paper mills, driving share upside potential of 50%-100%, according to Bloomberg. PRICE ACTION: In morning trading, shares of KapStone are up more than 6% to $31 following the MLP comments made on the call.
07:06 EDTMOSMosaic sees FY14 CapEx $1B-$1.2B
Subscribe for More Information
07:05 EDTMOSMosaic sees Q4 Potash total sales volume 2M-2.3M
Subscribe for More Information
07:05 EDTMOSMosaic sees Q4 Phosphates totalsales volume 2.5M-2.8M
Mosaic's realized DAP price, FOB plant, for the fourth quarter is estimated to range from $430 to $450 per tonne. Mosaic's gross margin rate in the segment is expected to be in the mid-teens percent range during the fourth quarter. The operating rate in the segment is expected to be in the 70 to 80 percent range reflecting on-going production curtailment to limit high cost inventory build-up.
07:04 EDTMOSMosaic reports Q3 Phosphates sales $1.7B, 3.3M tonnes
Reports Q3 Potash sales $593M, 18M tonnes.
07:03 EDTMOSMosaic: Improving potash/phosphates demand continued
Subscribe for More Information
07:03 EDTMOSMosaic reports Q3 EPS 54c, compared to 29c a year ago
Subscribe for More Information
October 29, 2014
15:41 EDTMOSNotable companies reporting before tomorrow's open
Subscribe for More Information
14:29 EDTNVSLannett announces FDA approval of Letrozole tablets
Subscribe for More Information
07:16 EDTMOSMosaic volatility elevated into Q3 and outlook
Mosaic October weekly call option implied volatility is at 46, November is at 25, December is at 21, January is at 25; compares to its 26-week average of 22 according to Track Data, suggesting large near term price movement into the expected release of Q3 results on October 30.
October 28, 2014
07:31 EDTNVSThe FDA to hold a workshop
First Annual Neonatal Scientific Workshop, "Roadmap for Applying Regulatory Science to Neonates" is being held at FDA Silver Spring, Maryland offices on October 28-29 at 8:30 am. Webcast Link
05:35 EDTNVSNovartis confirms FY14 revenue view of growth at a low to mid-single digit rate
Subscribe for More Information
05:31 EDTNVSNovartis reports Q3 core EPS $1.37, consensus $1.29
Subscribe for More Information
October 27, 2014
08:25 EDTNVSCSL to acquire Novartis' influenza vaccine business
Subscribe for More Information
07:29 EDTNVSWorldwide Business Research to hold a conference
ProcureCon Pharma 2014 is being held in Philadelphia on October 27-29.
06:28 EDTNVSVirbac acquires veterinary assets from Eli Lilly in U.S.
Virbac announces that it has entered into an agreement with Eli Lilly (LLY) to acquire "major" U.S. veterinary products currently marketed by Novartis (NVS) Animal Health. Eli Lilly has agreed to divest these U.S. assets in connection with the U.S. Federal Trade Commissionís review of Eli Lillyís pending acquisition of Novartis Animal Health worldwide. Under the terms of this agreement, Virbac would acquire a combination of titles and rights for the U.S. on trademarks, marketing authorizations, patents, know-how, customer lists and other assets, related to two parasiticides for dogs including Sentinel Flavor Tabs and Sentinel Spectrum, currently marketed in the U.S. by Novartis Animal Health. In the U.S., Sentinel Flavor tabs and Sentinel Spectrum are expected to reach total revenues of approximately $90M-$100M in 2014. Adding these brands and commercial franchise to the current Virbac portfolio of products offered to veterinary clinics and pet owners in the U.S. will strengthen Virbacís presence and penetration in the U.S. companion animal veterinary market and leverage its growth potential. The completion of this transaction is subject to approval by the Federal Trade Commission, which Virbac expects may be received in the near future. It is also conditioned on the closing of the acquisition of Novartis Animal Health by Eli Lilly and should occur shortly thereafter.
October 24, 2014
11:17 EDTADMArcher Daniels halts cocoa roasting at Schokinag facility, Reuters says
Subscribe for More Information
October 23, 2014
11:57 EDTNVSNovartis management to meet with Jefferies
Subscribe for More Information
10:22 EDTMOSMosaic upgraded to Buy from Hold at Standpoint Research
05:21 EDTNVSNovartis AIN457 meets primary endpoint in two Phase III studies in AS
Novartis announced that AIN457 met primary and key secondary endpoints in two pivotal Phase III studies, MEASURE 1 and MEASURE 2, in patients with ankylosing spondylitis, or AS. Key endpoints included improvements in signs and symptoms of the disease versus placebo and associated improvements in physical function and quality of life. Secukinumab is an investigational medicine that works by stopping the action of interleukin- 17A, a protein that is central to the development of inflammatory diseases, including AS. MEASURE 1 and MEASURE 2 enrolled a combined total of approximately 600 patients. Detailed results of the studies will be presented at an upcoming medical congress. Joint regulatory applications for secukinumab in AS and PsA are planned for 2015. This follows the secukinumab global regulatory applications for moderate- to-severe plaque psoriasis which were filed in October 2013 with regulatory decisions anticipated in late 2014 or early 2015.
October 22, 2014
07:44 EDTNVSGlaxoSmithKline backs FY14 view for core EPS 'broadly similar' to FY13
GlaxoSmithKline (GSK) continues to expect full year 2014 core EPS to be broadly similar to 2013 at CER and on ex-divestment basis. Glaxo says its proposed 3-part transaction with Novartis (NVS) is on track for completion in 1H15.
October 21, 2014
07:15 EDTNVSFDA to hold workshop on breast cancer drug development
Subscribe for More Information
October 20, 2014
15:09 EDTNVSNovartis reports FDA advisory committee recommends approval of secukinumab
Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee to the FDA voted unanimously to support the approval of AIN457, or secukinumab, a selective interleukin-17A inhibitor, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. A Biologics License Application for secukinumab is currently under FDA review with an anticipated action date in early 2015.
13:06 EDTIPInternational Paper initiated with a Buy at Dundee (pre-open)
Target $55.
09:32 EDTMOSMosaic upgraded to Outperform from Sector Perform at Scotia Capital
Subscribe for More Information
08:58 EDTMOSPartnerRe to provide $100M financing for Mosaic's home solar loan program
Subscribe for More Information
07:26 EDTNVSFDA Dermatologic & Ophthalmic Drugs Advisory Committee to hold a meeting
Subscribe for More Information
October 17, 2014
14:50 EDTNVSBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use